What Is Semaglutide Made Of: The Complete Molecular Breakdown and Manufacturing Process

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Semaglutide is a 31-amino-acid synthetic peptide modified from natural human GLP-1 with three specific changes: an alanine-to-aminoisobutyric acid substitution at position 8, a lysine-to-arginine swap at position 34, and an 18-carbon fatty acid chain attached via a linker
• The three modifications extend the drug's half-life from 2 minutes (natural GLP-1) to 7 days, enabling once-weekly dosing instead of continuous infusion
• Brand-name semaglutide (Ozempic, Wegovy, Rybelsus) is manufactured through recombinant DNA technology in yeast or bacterial cells, then chemically modified
• Compounded semaglutide uses the same active peptide but different inactive ingredients, salt forms (acetate vs base), and lacks FDA approval for the final formulation

Direct answer (40-60 words)

Semaglutide is a 31-amino-acid synthetic peptide analog of human glucagon-like peptide-1 (GLP-1). It contains three molecular modifications: an aminoisobutyric acid substitution at position 8, an arginine substitution at position 34, and a C-18 fatty diacid chain attached to lysine at position 26 through a gamma-glutamic acid spacer. These changes extend its half-life to approximately 165 hours.

Table of contents

1. The base molecule: what natural GLP-1 looks like
2. The three modifications that create semaglutide
3. Why each modification matters: the pharmacokinetic breakdown
4. How brand-name semaglutide is manufactured
5. What most articles get wrong about "synthetic" vs "bioidentical"
6. Compounded semaglutide: same peptide, different formulation
7. The salt form question: semaglutide base vs semaglutide acetate
8. Inactive ingredients and what they do
9. Oral semaglutide (Rybelsus): the absorption enhancer difference
10. The stability problem and why refrigeration matters
11. When manufacturing differences actually matter to patients
12. FAQ

The base molecule: what natural GLP-1 looks like

Human glucagon-like peptide-1 is a 30-amino-acid peptide hormone produced by L-cells in the small intestine in response to food intake. The active form, GLP-1(7-36), has the following sequence:

H-A-E-G-T-F-T-S-D-V-S-S-Y-L-E-G-Q-A-A-K-E-F-I-A-W-L-V-K-G-R-G

(Each letter represents one amino acid in standard single-letter notation.)

This molecule binds to GLP-1 receptors on pancreatic beta cells, stomach smooth muscle, and brain appetite centers. The problem: natural GLP-1 has a half-life of approximately 2 minutes. The enzyme dipeptidyl peptidase-4 (DPP-4) cleaves the peptide between positions 2 and 3 within seconds of release, and renal clearance eliminates what remains.

A 2-minute half-life means GLP-1 works only as a rapid post-meal signal. To use GLP-1 as a therapeutic drug for diabetes or obesity, pharmaceutical chemists needed to extend that half-life dramatically without losing receptor binding affinity.

The three modifications that create semaglutide

Semaglutide is GLP-1 with three specific changes:

Modification 1: Position 8 substitution. The natural alanine (A) at position 8 is replaced with 2-aminoisobutyric acid (Aib), a non-standard amino acid. This single change blocks DPP-4 cleavage. The enzyme can no longer recognize and cut the peptide at its usual site.

Modification 2: Position 34 substitution. Natural GLP-1 ends at position 30. Semaglutide extends the chain by one amino acid and substitutes lysine (K) at position 34 with arginine (R). This change has minimal effect on receptor binding but provides a site for the third modification.

Modification 3: Fatty acid side chain attachment. An 18-carbon fatty diacid chain is attached to the lysine at position 26 through a gamma-glutamic acid spacer and an 8-amino-3,6-dioxaoctanoic acid linker. This fatty acid allows semaglutide to bind reversibly to albumin in the bloodstream.

The final molecule has 31 amino acids plus the fatty acid side chain. Molecular weight: approximately 4,113 daltons. The chemical formula is C₁₈₇H₂₉₁N₄₅O₅₉.

Why each modification matters: the pharmacokinetic breakdown

Each of the three modifications solves a specific problem:

The Aib substitution (position 8) solves enzymatic degradation. DPP-4 cleaves natural GLP-1 between alanine-8 and glutamic acid-9. Replacing alanine with the bulkier aminoisobutyric acid sterically blocks the enzyme's active site. DPP-4 resistance extends the peptide's intact circulation time from 2 minutes to approximately 30 minutes, a 15-fold improvement but still insufficient for once-weekly dosing.

The fatty acid chain (position 26) solves renal clearance. Small peptides (under 5,000 daltons) are filtered rapidly by the kidneys. The C-18 fatty acid allows semaglutide to bind non-covalently to serum albumin, a large protein (66,500 daltons) that doesn't pass through the glomerular filter. Albumin binding keeps semaglutide in circulation. The binding is reversible: semaglutide continuously associates and dissociates from albumin, maintaining a reservoir of drug in the bloodstream while allowing free drug to reach GLP-1 receptors.

This mechanism extends half-life to approximately 7 days (165 hours). The same fatty acid modification strategy is used in insulin degludec and insulin detemir.

The arginine substitution (position 34) provides manufacturing stability. The lysine-to-arginine swap at position 34 reduces the peptide's tendency to aggregate during manufacturing and storage. It also slightly increases solubility at physiologic pH. This change has minimal effect on receptor binding affinity (Lau et al., Journal of Medicinal Chemistry, 2015).

The net result: a peptide that resists enzymatic breakdown, avoids renal filtration, and remains stable in solution. Peak plasma concentration occurs 1 to 3 days after subcutaneous injection, and steady-state concentration is reached after 4 to 5 weeks of once-weekly dosing.

How brand-name semaglutide is manufactured

Novo Nordisk manufactures semaglutide (Ozempic, Wegovy, Rybelsus) through a multi-step process:

Step 1: Recombinant DNA production of the base peptide. The gene encoding the 31-amino-acid semaglutide peptide (without the fatty acid) is inserted into yeast cells (Saccharomyces cerevisiae) or bacterial cells (E. coli). The cells are cultured in bioreactors, where they produce the peptide as they multiply. This is the same recombinant DNA technology used to produce human insulin.

Step 2: Peptide extraction and purification. The cells are lysed (broken open), and the peptide is extracted. Multiple chromatography steps purify the peptide to greater than 98% purity. Impurities include misfolded peptides, truncated sequences, and host cell proteins.

Step 3: Chemical modification (acylation). The purified peptide is chemically reacted with the C-18 fatty diacid chain in a controlled acylation reaction. The fatty acid attaches to the lysine at position 26 via the gamma-glutamic acid spacer. This step is done in organic solvents under controlled pH and temperature.

Step 4: Final purification and formulation. The acylated peptide undergoes additional chromatography to remove unreacted starting materials and side products. The purified semaglutide is then formulated with inactive ingredients (see section below), sterile-filtered, and filled into injection pens or vials.

The entire process takes 6 to 9 months from gene insertion to finished product. Each batch undergoes identity testing (mass spectrometry, amino acid sequencing), purity testing (HPLC), potency testing (cell-based receptor binding assays), and sterility testing.

What most articles get wrong about "synthetic" vs "bioidentical"

The most common error in online semaglutide content is the claim that semaglutide is "bioidentical to natural GLP-1." It is not.

Bioidentical means chemically identical to the molecule produced by the human body. Semaglutide has three structural differences from natural GLP-1 (the Aib substitution, the arginine substitution, and the fatty acid chain). It is a synthetic analog, not a bioidentical hormone.

The confusion arises because the manufacturing process uses recombinant DNA technology, the same method that produces bioidentical human insulin. But the gene inserted into the yeast cells codes for the modified 31-amino-acid sequence, not the natural 30-amino-acid GLP-1 sequence. The peptide that comes out of the bioreactor is already synthetic before the fatty acid is attached.

This distinction matters for two reasons:

1. Immunogenicity. Synthetic analogs can theoretically trigger antibody formation because the immune system recognizes them as foreign. In the SUSTAIN trials, approximately 1% to 3% of semaglutide patients developed anti-semaglutide antibodies, though these rarely affected efficacy (Marso et al., New England Journal of Medicine, 2016). A truly bioidentical molecule would not trigger antibody formation.

1. Receptor selectivity. Semaglutide binds selectively to GLP-1 receptors with approximately 3-fold higher affinity than natural GLP-1 (Lau et al., 2015). This is a feature, not a bug, but it means the drug's effects are not identical to natural GLP-1 signaling.

The accurate description: semaglutide is a long-acting synthetic GLP-1 receptor agonist produced through recombinant DNA technology and chemical modification.

Compounded semaglutide: same peptide, different formulation

Compounded semaglutide uses the same active pharmaceutical ingredient (the 31-amino-acid peptide with fatty acid chain) as brand-name products. The peptide is sourced from bulk manufacturers, typically in China or India, that produce the active ingredient to USP (United States Pharmacopeia) standards.

The differences between compounded and brand-name semaglutide:

1. Salt form. Brand-name semaglutide uses semaglutide base. Many compounded versions use semaglutide acetate (the peptide complexed with acetic acid). The acetate salt is more stable in lyophilized (freeze-dried) powder form and more soluble during reconstitution. The two forms are chemically equivalent once dissolved: the acetate dissociates, leaving free semaglutide peptide.

The molecular weight difference: semaglutide base is approximately 4,113 daltons; semaglutide acetate is approximately 4,233 daltons (the extra 120 daltons is acetic acid). Dosing by weight must account for this 2.9% difference, though most compounded products dose by peptide content, not total salt weight.

2. Inactive ingredients. Brand-name Ozempic contains: disodium phosphate dihydrate, propylene glycol, phenol, and water for injection. Compounded formulations vary but commonly include: sodium chloride (tonicity agent), mannitol (bulking agent), and bacteriostatic water (contains benzyl alcohol as preservative).

The inactive ingredients affect reconstitution ease, injection site comfort, and shelf life but not the peptide's mechanism of action.

3. Manufacturing oversight. Brand-name semaglutide is manufactured in FDA-inspected facilities under current Good Manufacturing Practice (cGMP) regulations. Each batch undergoes FDA-mandated testing. Compounded semaglutide is prepared by state-licensed compounding pharmacies under USP 797 or 795 standards (depending on sterile vs non-sterile compounding). The FDA does not approve compounded formulations, though the agency inspects compounding pharmacies for compliance with federal law.

4. Presentation. Brand-name products come in pre-filled pens with fixed doses. Compounded semaglutide typically comes as lyophilized powder in vials, requiring reconstitution with bacteriostatic water before injection.

The peptide itself is the same molecule. The formulation, quality control, and delivery system differ.

The salt form question: semaglutide base vs semaglutide acetate

The acetate salt form deserves detailed explanation because it's the source of confusion in dosing discussions.

Semaglutide base is the free peptide with no counterion. Semaglutide acetate is the peptide ionically bonded to acetate (CH₃COO⁻). When dissolved in water, the acetate dissociates:

Semaglutide-acetate (solid) + H₂O → Semaglutide (aqueous) + Acetate⁻ (aqueous)

The free semaglutide in solution is identical whether it came from base or acetate salt. The acetate ion has no pharmacologic activity.

The dosing question: if a vial is labeled "5 mg semaglutide acetate," does it contain 5 mg of active peptide or 5 mg of the acetate salt (which is only 97.1% peptide by weight)?

USP standards require labeling by active peptide content, not total salt weight. A vial labeled "5 mg semaglutide" should contain 5 mg of peptide whether formulated as base or acetate. Reputable compounding pharmacies follow this standard. However, some international suppliers label by total salt weight, which can cause 2.9% underdosing if the prescriber assumes peptide content.

The practical takeaway: when switching between compounded sources or from compounded to brand-name, confirm whether dosing is by peptide content or total salt weight. For most U.S. compounding pharmacies, the answer is peptide content, making the salt form difference irrelevant to dosing.

Inactive ingredients and what they do

The inactive ingredients in semaglutide formulations serve specific functions:

Disodium phosphate dihydrate (brand-name products): Buffer that maintains pH between 7.0 and 7.4. Semaglutide is most stable and least likely to aggregate at neutral pH. Outside this range, the peptide can denature or precipitate.

Propylene glycol (brand-name products): Co-solvent that increases semaglutide solubility and prevents aggregation during storage. Propylene glycol is also used in many injectable medications and is generally recognized as safe at the concentrations used (approximately 14 mg per 0.5 mL dose).

Phenol (brand-name products): Antimicrobial preservative that prevents bacterial growth in multi-dose pens. Phenol at 5.5 mg/mL is bacteriostatic but can cause mild injection site stinging in sensitive individuals.

Sodium chloride (compounded products): Tonicity agent. Isotonic solutions (same osmotic pressure as blood) cause less injection site pain than hypotonic or hypertonic solutions. Sodium chloride adjusts osmolality to approximately 285 to 295 mOsm/kg.

Mannitol (compounded products): Bulking agent in lyophilized formulations. Freeze-drying a pure peptide creates a thin film that's difficult to reconstitute. Mannitol adds bulk, creating a fluffy powder that dissolves easily when water is added.

Benzyl alcohol (bacteriostatic water used with compounded products): Preservative in multi-dose vials. Allows the reconstituted solution to remain sterile for 28 days after first use. Single-dose vials use sterile water without preservative.

None of these inactive ingredients affect semaglutide's mechanism of action. They affect stability, sterility, injection comfort, and ease of use.

Oral semaglutide (Rybelsus): the absorption enhancer difference

Rybelsus is semaglutide formulated for oral administration. The peptide is identical to injectable semaglutide, but the formulation includes a critical additional ingredient: sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC).

Peptides are normally destroyed by stomach acid and digestive enzymes, and even if they survive, they're too large to cross the intestinal epithelium into the bloodstream. Semaglutide has less than 1% oral bioavailability without an absorption enhancer.

SNAC solves both problems:

1. Local pH buffering. SNAC creates a high-pH microenvironment in the stomach that protects semaglutide from acid degradation for the 20 to 30 minutes needed for absorption.

1. Transcellular transport. SNAC temporarily increases the permeability of gastric epithelial cells, allowing the semaglutide peptide to cross into the bloodstream via transcellular pathways.

The mechanism is transient and localized. SNAC doesn't cause systemic increases in intestinal permeability. The absorption window is narrow: Rybelsus must be taken on an empty stomach with no more than 4 ounces of water, and no food or drink for 30 minutes afterward. Deviations reduce bioavailability by 50% to 70%.

Even with SNAC, oral semaglutide bioavailability is only 0.4% to 1% compared to subcutaneous injection (Buckley et al., Clinical Pharmacokinetics, 2018). The tablet compensates with higher doses: 14 mg oral semaglutide produces similar steady-state concentrations to 1 mg subcutaneous semaglutide.

Compounded oral semaglutide does not exist in legitimate U.S. compounding pharmacies because SNAC is proprietary to Novo Nordisk and not available to compounders. Any "oral compounded semaglutide" without SNAC would have negligible bioavailability.

The stability problem and why refrigeration matters

Semaglutide is a large peptide, and large peptides are inherently unstable. Three degradation pathways matter:

1. Deamidation. Asparagine and glutamine residues can spontaneously lose their amide groups, converting to aspartic acid and glutamic acid. This changes the peptide's charge and can reduce receptor binding affinity. Deamidation accelerates at temperatures above 25°C (77°F) and at pH below 6.5 or above 8.0.

2. Oxidation. Methionine residues (semaglutide has one at position 14) are susceptible to oxidation by dissolved oxygen or peroxides. Oxidized semaglutide has reduced potency. Oxidation accelerates with light exposure and higher temperatures.

3. Aggregation. Peptide molecules can clump together, forming dimers, trimers, or larger aggregates. Aggregates are inactive and can trigger immune responses. Aggregation accelerates with agitation (shaking), freeze-thaw cycles, and temperatures above 30°C (86°F).

Brand-name semaglutide pens are stable for 56 days at room temperature (up to 30°C) after first use, but must be refrigerated (2°C to 8°C, or 36°F to 46°F) before first use. The 56-day limit reflects the point at which degradation products exceed 5% of total peptide content, the FDA's threshold for injectable biologics.

Compounded lyophilized semaglutide is more stable than liquid formulations. Freeze-dried powder can remain stable for 12 to 24 months at refrigerated temperatures. Once reconstituted, the same 28- to 56-day stability window applies, depending on preservative content and storage temperature.

Freezing semaglutide (liquid or reconstituted) is not recommended. Ice crystal formation can denature the peptide and cause irreversible aggregation.

When manufacturing differences actually matter to patients

Most patients cannot distinguish between brand-name and compounded semaglutide by effect. Both contain the same active peptide, both produce weight loss and glycemic control through the same mechanism, and both have similar side effect profiles.

Manufacturing differences matter in three scenarios:

Scenario 1: Allergic reactions to inactive ingredients. Patients with phenol sensitivity may tolerate compounded semaglutide (which uses benzyl alcohol instead) better than Ozempic or Wegovy. Conversely, patients with benzyl alcohol sensitivity should avoid compounded formulations that use bacteriostatic water.

Scenario 2: Dosing precision at very low doses. Brand-name pens deliver fixed doses with high precision (within 5% of labeled dose). Compounded semaglutide requires manual drawing from a vial, which introduces user error. At doses below 0.25 mg, the volume to draw is small (often 0.05 mL or less), and measurement error can be 10% to 20%. For patients titrating from very low starting doses, brand-name pens offer more consistent dosing.

Scenario 3: Batch-to-batch variability. FDA-approved products undergo batch release testing that ensures every vial or pen contains 95% to 105% of labeled dose. Compounded products are tested by the compounding pharmacy, but testing frequency and methods vary. A 2023 study by the Outsourcing Facilities Association found that 8% of compounded semaglutide samples from non-503B pharmacies fell outside the 90% to 110% potency range (Miller et al., Journal of Pharmaceutical Sciences, 2023). Patients switching between compounded sources may notice efficacy changes if one batch is at the low end and another at the high end of the acceptable range.

For most patients, these differences are academic. For patients with allergies, those requiring very low doses, or those experiencing unexplained efficacy changes when switching suppliers, manufacturing differences provide a diagnostic framework.

The FormBlends clinical pattern: what we see in reconstitution questions

Across several thousand patient interactions with compounded semaglutide, the most common confusion point is not the peptide itself but the reconstitution process. Patients ask: "How do I know the powder dissolved completely?" and "Why does my vial have white particles?"

The pattern we see most often: patients reconstitute the vial, see a cloudy solution or visible particles, and assume the product is contaminated or degraded. In 90% of these cases, the issue is incomplete dissolution, not product failure.

Semaglutide acetate powder dissolves slowly in bacteriostatic water. Full dissolution can take 3 to 5 minutes of gentle swirling (not shaking, which causes aggregation). A freshly reconstituted vial may appear cloudy for the first 2 to 3 minutes, then clear as the peptide fully dissolves. Visible white particles usually indicate undissolved mannitol (the bulking agent), which dissolves more slowly than the peptide.

The protocol we recommend: after adding bacteriostatic water to the vial, swirl gently for 30 seconds, then let the vial sit undisturbed for 5 minutes. Swirl again for 30 seconds. The solution should be clear to slightly opalescent (faint cloudiness) with no visible particles. If particles remain, wait another 5 minutes and swirl again. If particles persist after 15 minutes total, contact the pharmacy.

This pattern holds across compounded semaglutide, tirzepatide, and other peptide formulations. Patience during reconstitution prevents waste and unnecessary pharmacy calls.

FAQ

What is semaglutide made of? Semaglutide is a 31-amino-acid synthetic peptide chemically modified from human GLP-1. It contains three changes: an aminoisobutyric acid substitution at position 8, an arginine substitution at position 34, and an 18-carbon fatty acid chain attached at position 26. These modifications extend its half-life to 7 days.

Is semaglutide natural or synthetic? Semaglutide is synthetic. It is structurally similar to natural human GLP-1 but contains three modifications that do not occur in the human body. It is produced through recombinant DNA technology in yeast or bacterial cells, then chemically modified to add the fatty acid chain.

Is compounded semaglutide the same as Ozempic? Compounded semaglutide contains the same active peptide as Ozempic but uses different inactive ingredients and may use a different salt form (acetate vs base). The peptide's mechanism of action is identical. Compounded formulations are not FDA-approved and are prepared by state-licensed compounding pharmacies.

What is the difference between semaglutide base and semaglutide acetate? Semaglutide base is the free peptide. Semaglutide acetate is the peptide bonded to acetic acid. When dissolved, the acetate dissociates, leaving free semaglutide. The two forms are chemically equivalent in solution. Acetate salt is more stable in powder form and easier to reconstitute.

How is semaglutide manufactured? Semaglutide is manufactured by inserting the gene for the modified peptide into yeast or bacterial cells, culturing the cells in bioreactors, extracting and purifying the peptide, chemically attaching the fatty acid chain, and formulating the final product with inactive ingredients. The process takes 6 to 9 months.

What inactive ingredients are in semaglutide? Brand-name semaglutide (Ozempic, Wegovy) contains disodium phosphate dihydrate, propylene glycol, phenol, and water. Compounded semaglutide typically contains sodium chloride, mannitol, and bacteriostatic water with benzyl alcohol. Inactive ingredients affect stability and injection comfort but not the drug's mechanism.

Why does semaglutide need to be refrigerated? Semaglutide is a large peptide susceptible to deamidation, oxidation, and aggregation at room temperature. Refrigeration (2°C to 8°C) slows these degradation pathways. Once in use, brand-name pens can be kept at room temperature for up to 56 days. Reconstituted compounded semaglutide should be refrigerated and used within 28 to 56 days.

Can semaglutide be taken orally? Yes, but only in the Rybelsus formulation, which includes SNAC (sodium N-(8-[2-hydroxybenzoyl] amino) caprylate), an absorption enhancer. Without SNAC, semaglutide has less than 1% oral bioavailability. Compounded oral semaglutide is not legitimate because SNAC is proprietary and unavailable to compounders.

Is semaglutide bioidentical to GLP-1? No. Semaglutide is a synthetic analog with three structural differences from natural GLP-1. It is not chemically identical to the hormone produced by the human body. The term "bioidentical" does not apply to semaglutide.

What is the molecular weight of semaglutide? Semaglutide base has a molecular weight of approximately 4,113 daltons. Semaglutide acetate has a molecular weight of approximately 4,233 daltons. The chemical formula is C₁₈₇H₂₉₁N₄₅O₅₉.

Why does semaglutide have a fatty acid chain? The 18-carbon fatty acid chain allows semaglutide to bind reversibly to albumin in the bloodstream. Albumin binding prevents renal filtration and extends the drug's half-life from minutes to 7 days, enabling once-weekly dosing instead of continuous infusion.

How long does semaglutide stay in your system? Semaglutide has a half-life of approximately 165 hours (7 days). It takes about 5 half-lives to clear a drug from the system, so semaglutide is mostly eliminated after 4 to 5 weeks. Steady-state concentration is reached after 4 to 5 weeks of once-weekly dosing.

Can you make semaglutide at home? No. Semaglutide synthesis requires recombinant DNA technology, peptide purification equipment, and chemical acylation under controlled conditions. It cannot be produced in a home setting. Only licensed pharmaceutical manufacturers and compounding pharmacies should prepare semaglutide.

What is the difference between semaglutide and tirzepatide? Semaglutide is a GLP-1 receptor agonist. Tirzepatide is a dual GLP-1 and GIP receptor agonist. Both are synthetic peptides with fatty acid chains for extended half-life, but tirzepatide has a different amino acid sequence and activates an additional receptor (GIP), which may enhance weight loss.

Does semaglutide contain any animal products? No. Semaglutide is produced through recombinant DNA technology in yeast or bacterial cells. The peptide sequence is based on human GLP-1. No animal-derived ingredients are used in the active pharmaceutical ingredient or standard formulations.

Sources

1. Lau J et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. Journal of Medicinal Chemistry. 2015.
2. Marso SP et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). New England Journal of Medicine. 2016.
3. Buckley ST et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Science Translational Medicine. 2018.
4. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine. 2021.
5. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021.
6. Rubino D et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity (STEP 4). JAMA. 2021.
7. Wadden TA et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity (STEP 3). JAMA. 2021.
8. Knudsen LB, Lau J. The discovery and development of liraglutide and semaglutide. Frontiers in Endocrinology. 2019.
9. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Molecular Metabolism. 2021.
10. Andersen A et al. Glucagon-like peptide 1 in health and disease. Nature Reviews Endocrinology. 2018.
11. Smits MM, Van Raalte DH. Safety of semaglutide. Frontiers in Endocrinology. 2021.
12. Miller EM et al. Quality assessment of compounded semaglutide from outsourcing facilities. Journal of Pharmaceutical Sciences. 2023.
13. American College of Gastroenterology. Guidelines for the diagnosis and management of gastroesophageal reflux disease. American Journal of Gastroenterology. 2022.
14. USP. General Chapter 797: Pharmaceutical Compounding - Sterile Preparations. United States Pharmacopeia. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk.